467 related articles for article (PubMed ID: 29031731)
21. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM; Censani M
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity.
René P; Lanfray D; Richard D; Bouvier M
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434184
[TBL] [Abstract][Full Text] [Related]
23. A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity.
Rettenbacher E; Tarnow P; Brumm H; Prayer D; Wermter AK; Hebebrand J; Biebermann H; Hinney A; Widhalm K
Exp Clin Endocrinol Diabetes; 2007 Jan; 115(1):7-12. PubMed ID: 17286227
[TBL] [Abstract][Full Text] [Related]
24. Cardiac Phenotype and Tissue Sodium Content in Adolescents With Defects in the Melanocortin System.
Puder L; Roth S; Krabusch P; Wiegand S; Opitz R; Bald M; Flück C; Schulz E; Voss E; Markó L; Linz P; Berger F; Müller DN; Kuehne T; Litt MJ; Cone RD; Kühnen P; Kelm M
J Clin Endocrinol Metab; 2021 Aug; 106(9):2606-2616. PubMed ID: 34036349
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Strategies Against Metabolic Imbalance in a Male Mouse Model With 5-HT2CR Loss-of-Function.
Liu H; Liu Z; Wong HK; Xu N; Liu Q; Li Y; Liu Y; Wong H; Burt ME; Jossy SV; Han J; He Y
Endocrinology; 2024 May; 165(7):. PubMed ID: 38815086
[TBL] [Abstract][Full Text] [Related]
26. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.
Xiang Z; Proneth B; Dirain ML; Litherland SA; Haskell-Luevano C
Biochemistry; 2010 Jun; 49(22):4583-600. PubMed ID: 20462274
[TBL] [Abstract][Full Text] [Related]
28. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
[TBL] [Abstract][Full Text] [Related]
29. Two Cases With an Early Presented Proopiomelanocortin Deficiency-A Long-Term Follow-Up and Systematic Literature Review.
Gregoric N; Groselj U; Bratina N; Debeljak M; Zerjav Tansek M; Suput Omladic J; Kovac J; Battelino T; Kotnik P; Avbelj Stefanija M
Front Endocrinol (Lausanne); 2021; 12():689387. PubMed ID: 34177811
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity.
René P; Le Gouill C; Pogozheva ID; Lee G; Mosberg HI; Farooqi IS; Valenzano KJ; Bouvier M
J Pharmacol Exp Ther; 2010 Dec; 335(3):520-32. PubMed ID: 20826565
[TBL] [Abstract][Full Text] [Related]
31. Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use.
Le Collen L; Delemer B; Poitou C; Vaxillaire M; Toussaint B; Dechaume A; Badreddine A; Boissel M; Derhourhi M; Clément K; Petit JM; Mau-Them FT; Bruel AL; Thauvin-Robinet C; Saveanu A; Cherifi BG; Le Beyec-Le Bihan J; Froguel P; Bonnefond A
Genet Med; 2023 Jul; 25(7):100857. PubMed ID: 37092539
[TBL] [Abstract][Full Text] [Related]
32. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
[TBL] [Abstract][Full Text] [Related]
33. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
[TBL] [Abstract][Full Text] [Related]
34. Assessment of voluntary ethanol consumption and the effects of a melanocortin (MC) receptor agonist on ethanol intake in mutant C57BL/6J mice lacking the MC-4 receptor.
Navarro M; Lerma-Cabrera JM; Carvajal F; Lowery EG; Cubero I; Thiele TE
Alcohol Clin Exp Res; 2011 Jun; 35(6):1058-66. PubMed ID: 21332528
[TBL] [Abstract][Full Text] [Related]
35. Desacetyl-α-melanocyte stimulating hormone and α-melanocyte stimulating hormone are required to regulate energy balance.
Mountjoy KG; Caron A; Hubbard K; Shome A; Grey AC; Sun B; Bould S; Middleditch M; Pontré B; McGregor A; Harris PWR; Kowalczyk R; Brimble MA; Botha R; Tan KML; Piper SJ; Buchanan C; Lee S; Coll AP; Elmquist JK
Mol Metab; 2018 Mar; 9():207-216. PubMed ID: 29226825
[TBL] [Abstract][Full Text] [Related]
36. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
[TBL] [Abstract][Full Text] [Related]
37. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects.
Tao YX; Segaloff DL
J Clin Endocrinol Metab; 2005 Oct; 90(10):5632-8. PubMed ID: 16030156
[TBL] [Abstract][Full Text] [Related]
38. MC4R variants modulate α-MSH and setmelanotide induced cellular signaling at multiple levels.
Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38567654
[TBL] [Abstract][Full Text] [Related]
39. Setmelanotide (Imcivree) for rare genetic forms of obesity.
Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
[No Abstract] [Full Text] [Related]
40. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
Kievit P; Halem H; Marks DL; Dong JZ; Glavas MM; Sinnayah P; Pranger L; Cowley MA; Grove KL; Culler MD
Diabetes; 2013 Feb; 62(2):490-7. PubMed ID: 23048186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
